



Contact:

David Waldman or Justyna Gudaszewska
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: +48 693 354 580

**Key Opinion Leader Reports 100% Success Rate in more than 150 Procedures
Using Milestone Medical's CompuFlo® Epidural System**

Assistant Professor of Anesthesiology at University of Chile calls CompuFlo® Instrument "A new and powerful tool to make our specialty even more secure"

LIVINGSTON, NJ, November 7, 2017 -- Milestone Medical Inc. (WAR:MMD) today provided the following testimonial from Dr. Guillermo Hidalgo Vallés, a leading anesthesiologist and key opinion leader in South America. Dr. Hidalgo is an Assistant Professor of Anesthesiology at the University of Chile and Anesthesiologist at the Clinica Alemana de Santiago.

Dr. Hidalgo, commented, "Successful epidural anesthesia is based on acuity in the technique of puncture. This requires an adequate palpation of the space to be punctured, a good local anesthesia, carefully advancing the Tuohy needle, and detecting the tactile sensations of each tissue and the corresponding feeling of resistance to compression of the plunger using the low resistance syringe. The operator must 'know' that he has reached the epidural space and confirm this finding with the loss of resistance of the low resistance syringe. This is a fundamental aspect of the 'art' of the epidural puncture.

"Initially, I was a little afraid to perform the puncture by forgoing the usual manual sensations that come with the low resistance syringe, but I quickly realized that the correlation between the advancing hand with the Tuohy needle and the images and sounds of the CompuFlo® are very reliable.

"In 100% of more than 150 procedures that I performed, I have been able to verify that CompuFlo® has the ability to transform those tactile sensations of the operator into graphical signs reflecting the pressure curve and accurate colors and sounds that reaffirm the findings to the less experienced operator. In the field of teaching, I believe CompuFlo® will be a very valuable tool since it will guide the student without the instructor having to intervene directly as we usually do. The more experienced anesthesiologist will gain benefits in difficult punctures (obesity, edema, anatomical alterations, cervical or thoracic punctures, etc.) and, when necessary, provides the ability to document the arrival of the needle into the epidural space, such as when a blood patch is performed. As we increase cases, we will accumulate more experience, but my impression is that we have a new and powerful tool to make our specialty even more secure."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.